Stifel raised the firm’s price target on Idexx Laboratories to $570 from $525 and keeps a Hold rating on the shares. The company’s results and guidance “were not heroic,” argues the analyst, who contends that the move in shares is “likely all attributable to multiple expansion.” However, the firm believes shares may take a pause, even though it adds that the “components of the revenue growth algo were likely better than people expected.”
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on IDXX:
- Idexx Laboratories sees 2024 EPS $10.84-$11.33, consensus $11.00
- Idexx Laboratories reports Q4 EPS $2.32 with items, consensus $2.12
- Is IDXX a Buy, Before Earnings?
- Idexx Laboratories downgraded to Neutral from Overweight at Piper Sandler
- Idexx Laboratories price target raised to $600 from $545 at BofA